By Sam Baker - 10/12/11 08:13 PM EDT
“As we look to cut costs, it only makes sense to extend the kinds of discounts that are holding costs down in Medicaid to Medicare Part B,” Kohl said in a statement.
The pharmaceutical industry strongly opposes all three proposals. Keeping them off the table was a large part of the industry's motivation for striking a controversial $80 billion deal to support healthcare reform. But many Democrats have renewed their push for lower drug spending as the supercommittee looks to health programs for savings.